¼¿ï´ëÇб³ Ä¡°úº´¿ø 2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2019-07-12±³À°ÀÏÀÚ : 2019-07-12
±³À°Àå¼Ò : ¼¿ï´ëÇб³ Ä¡°úº´¿ø 8Ãþ °´ç
±³À°ÁÖÁ¦ :
2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇìÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
bmt@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-12 °´ç 10:00~10:30 Overview of cellular immunotherapy for cancer ±èűÔ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 10:30~11:00 Development of a new platform for T cell immunotherapy: Avidity control of T-cell antigen receptor and adhesion receptors Àüâ´ö(GIST)
±³À°½Ã°£ 07-12 °´ç 11:00~11:30 Evolution of CAR-T therapy ±èÂùÇõ(KAIST)
±³À°½Ã°£ 07-12 °´ç 11:30~12:00 Recent advances in cell reprogramming and gene targeting as new therapies for neurodegenerative disease ±èÁ¾ÇÊ(µ¿±¹´ë)
±³À°½Ã°£ 07-12 °´ç 13:00~13:30 Natural killer cell therapy and monoclonal antibodies Á¶´ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 13:30~14:00 Recent advances of CAR-T cell therapy in lymphoma/myeloma À±´öÇö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 14:00~14:30 Real-world experiences of CAR T cell therapy in pediatric ALL: efficacy and toxicity °í°æ³²(¿ï»êÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 14:30~15:00 Mesenchymal stem cells in hematopoietic stem cell transplantation À¯°ÇÈñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 15:20~15:50 Clinical & immunological evaluation of cellular immunotherapy in cancer patients ȲÀ¯°æ(GC³ì½ÊÀÚ·¦¼¿)
±³À°½Ã°£ 07-12 °´ç 15:50~16:20 Clinical trial of dendritic cell therapy with immunomodulating agents in myeloma Á¤¼ºÈÆ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 07-12 °´ç 16:20~16:50 Clinical trial design for cellular immunotherapy ¾Èº´Áø(¾¾¾Ø¾Ë¸®¼Ä¡)